A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors

NCT05217693 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
288
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bliss Biopharmaceutical (Hangzhou) Co., Ltd